coadministered cagrilintide and semaglutide in adults with overweight or obesity New in the August 14,

New in the August 14, 2025, issue of NEJM: CagrilintideSemaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintidesemaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial results Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity New England Journal of Medicine https: t.co PBzCVl7Uba @ParagSinghal09 Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti Obesity Medications: A Systematic Review and Meta Analysis PMC The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies

SKU: 83931719633 · From metron-ms.com